Trexquant Investment LP Buys Shares of 9,579 Aclaris Therapeutics Inc (ACRS)
Trexquant Investment LP bought a new position in Aclaris Therapeutics Inc (NASDAQ:ACRS) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 9,579 shares of the biotechnology company’s stock, valued at approximately $247,000.
Other hedge funds have also bought and sold shares of the company. Citigroup Inc. raised its stake in Aclaris Therapeutics by 171.8% during the 2nd quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 2,726 shares during the last quarter. UBS Group AG raised its stake in Aclaris Therapeutics by 60.4% during the 1st quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 1,681 shares during the last quarter. Legal & General Group Plc raised its stake in Aclaris Therapeutics by 98.3% during the 2nd quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock valued at $142,000 after purchasing an additional 2,605 shares during the last quarter. Bank of Montreal Can raised its stake in shares of Aclaris Therapeutics by 1,793.1% in the 2nd quarter. Bank of Montreal Can now owns 7,137 shares of the biotechnology company’s stock valued at $194,000 after buying an additional 6,760 shares in the last quarter. Finally, Voya Investment Management LLC bought a new stake in shares of Aclaris Therapeutics in the 2nd quarter worth about $247,000. 92.10% of the stock is owned by institutional investors.
Shares of Aclaris Therapeutics Inc (NASDAQ ACRS) opened at $22.11 on Friday. Aclaris Therapeutics Inc has a fifty-two week low of $21.32 and a fifty-two week high of $33.25.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.23. The company had revenue of $0.68 million for the quarter, compared to analyst estimates of $2.00 million. sell-side analysts anticipate that Aclaris Therapeutics Inc will post -2.59 earnings per share for the current year.
Several equities research analysts have recently weighed in on the stock. BidaskClub raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Zacks Investment Research lowered shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. JMP Securities reissued an “outperform” rating and set a $39.00 price objective on shares of Aclaris Therapeutics in a report on Friday, September 8th. Cantor Fitzgerald reissued a “buy” rating and set a $50.00 price objective on shares of Aclaris Therapeutics in a report on Tuesday, September 26th. Finally, ValuEngine downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $39.20.
Aclaris Therapeutics Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics Inc (NASDAQ:ACRS).
Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.